Latest news with #PrashantMathur
New Indian Express
01-07-2025
- Health
- New Indian Express
AMPOK announces cancer research grant worth Rs 5 lakh
THIRUVANANTHAPURAM: The Association of Medical and Paediatric Oncologists of Kerala (AMPOK) announced a research grant of Rs 5 lakh for cancer research at the Kerala Cancer Conclave 2025, which concluded on Sunday. The announcement comes at a time when experts are raising concerns about the quality of cancer studies, which are crucial for the prevention and treatment of cancer in the state. According to data presented by Prashant Mathur, Director of the National Centre for Disease Informatics and Research (NCDIR), by 2030, cancer is expected to affect 45,813 women and 43,930 men in Kerala. Dr Boben Thomas, secretary of AMPOK, revealed that 'Kerala Cancer Conclave 2.0' would be held in the future, promising further advancements and collaborations in the fight against cancer. Over the course of two days, the conclave featured extensive discussions on eight key topics and four dedicated scientific sessions. More than 50 esteemed speakers, including leading oncologists, healthcare policymakers, researchers, and industry leaders from around the world, participated in the event. On the final day, Dr Shaji Kumar, the Mark and Judy Mullins Professor of Hematological Malignancies and Chair of the Myeloma and Amyloidosis Group at Mayo Clinic, discussed the next-generation tools for cancer treatment, including CAR-T cell therapy and bispecific antibodies. Additionally, renowned artist B D Dethan performed a live painting during the inaugural ceremony, and AMPOK acquired the artwork. The event featured the launch of a special souvenir magazine, 'Stories That Heal, Visions That Inspire,' a heartfelt collection of reflections and insights from over twenty esteemed oncologists of Kerala origin. The first copy was unveiled by the souvenir's editor, Dr Ashok S Komaranchath, and presented to the dignitaries.
Business Standard
30-06-2025
- Business
- Business Standard
Saatvik Green Energy Wins 'Brand of the Year'; CEO Prashant Mathur Named 'CEO of the Year' at Outlook Business Leadership Awards 2025
VMPL Bengaluru (Karnataka) [India], June 30: Saatvik Green Energy Limited (SGEL) has been honoured as 'Brand of the Year', while its Chief Executive Officer (CEO), Mr. Prashant Mathur, has been recognised as 'CEO of the Year' at the Outlook Business Spotlight Enterprise & Leadership Awards 2025, held at the Taj MG Road, Bengaluru. These prestigious awards acknowledge enterprise excellence and strategic leadership in India's evolving business landscape. The Outlook Business Spotlight platform celebrates organizations that demonstrate innovation, resilience, and operational discipline, and honours leaders whose strategic clarity and people-first approach have inspired impact and integrity in execution. The 'Brand of the Year' recognition highlights Saatvik Green Energy Limited's positioning as a trusted Indian brand in the clean energy space. The 'CEO of the Year' honour conferred upon Mr. Mathur reflects his stewardship in shaping a focused, purpose-driven culture anchored in sound governance and performance. Commenting on the recognition, Mr. Prashant Mathur, CEO, SGEL said: "I'm truly humbled to receive the 'CEO of the Year' recognition, and equally proud that Saatvik Green Energy Limited has been named 'Brand of the Year' by Outlook Business. These awards are a reflection of the collective commitment of our teams across India, who have worked with integrity, focus, and resilience to build Saatvik into a trusted name in the clean energy sector. We see this not as a destination, but as a reminder of what disciplined execution and shared values can achieve together. Thank you for this honour." This recognition comes at a defining moment for Saatvik Green Energy Limited (SGEL), as the company recently earned the Great Place to Work® Certification, and the 'ET Now Best Organisations to Work' award as well, a reflection of its people-first culture and transparent work environment. Additionally, the year 2025 marks the successful completion of 10 years of operational excellence for Saatvik--a decade shaped by a strong foundation of trust, integrity, and commitment to clean energy innovation across India and global markets. About Saatvik Green Energy Limited SGEL is one of India's leading module manufacturers, in terms of operational solar PV module manufacturing capacity, with an operational capacity of approximately 3.80 GW modules as of February 28, 2025. The SGEL offers Mono PERC and N-TopCon modules, EPC services, and O & M capabilities. Disclaimer: SAATVIK GREEN ENERGY LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offering of its Equity Shares and has filed the DRHP with SEBI and Stock Exchanges on March 13, 2025. The DRHP is available on the websites of SEBI, BSE and NSE at and respectively, and on the websites of the Book Running Lead Managers i.e. DAM Capital Advisors Limited at Ambit Private Limited at and Motilal Oswal Investment Advisors Limited at respectively and also at the website of the Company at investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 54 of the DRHP. Potential investors should not rely on the DRHP for making any investment decisions. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act), pursuant to the private placement exemption set out in Section 4(a) of the U.S. Securities Act.
Time of India
29-06-2025
- Health
- Time of India
New study warns of rising cancer burden in Kerala
T'puram: A recent study presented at the Kerala Cancer Conclave 2025 reveals alarming cancer trends in the state, with Kerala reporting an average 88,460 cases annually-43,110 among males and 45,350 among females. The national average stands at 1.56 million cases, making Kerala's contribution significant at nearly 5.7% of India's total cancer burden. By 2030, projections indicate a further rise to 43,930 cases in men and 45,813 in women. The report presented by Prof Prashant Mathur, Director, ICMR-National Center for Disease Informatics and Research, Bengaluru, points to stark gender-based disparities in cancer prevalence. Among men, lung cancer leads at 14%, followed by oral cavity (10%), colorectal (10%), prostate (9%), and liver cancers (8%). For women, breast cancer dominates at 34%, with thyroid (11%), colorectal (9%), uterine (6%), and ovarian cancers (4%) following. Among males, the most common cancers were lung (14%), oral cavity (10%), colorectum (10%), prostate (9%), and Jliver (8%). In females, breast cancer accounted for a striking 34%, followed by thyroid (11%), colorectum (9%), corpus uteri (6%), and ovary (4%). Dr Mathur highlighted the rising prevalence of lung, prostate, and liver cancers in men, and breast and thyroid cancers in women. Liver cancer, in particular, continues to show a rapid increase across both genders over the past two decades. In terms of crude mortality rates in Kerala in 2024, lung cancer led among men at 28.9%, followed by liver (18.9%), prostate (11.2%), stomach (8.3%), and mouth (8.3%). For women, breast cancer had the highest crude mortality rate at 37.5%, followed by lung (8.3%), ovary (6.6%), thyroid (6.1%), and cervix uteri (5.2%). Lung cancer mortality among men in the state is 28.9%, while the national average is only 7.8%. For breast cancer in women, Kerala's mortality rate is 37.5%, far above the national average of 14.9%.
New Indian Express
29-06-2025
- Health
- New Indian Express
Cancer burden in Kerala set to rise by 2030; breast, lung cancer leading
THIRUVANANTHAPURAM: The National Centre for Disease Informatics and Research (NCDIR) projects that by 2030, every year cancer will affect 45,813 women and 43,930 men in Kerala. This forecast, shared at the Kerala Cancer Conclave organised by the Association of Medical and Pediatric Oncologists of Kerala (AMPOK), reflects growing concerns among medical experts regarding the increasing cancer burden in the state. In 2024, 43,110 men and 45,008 women were diagnosed with cancer, making the projected rise seem relatively modest. However, Dr. Prashant Mathur, Director of ICMR-NCDIR, which oversees the country's cancer registries, emphasised that the growth in Kerala, which is already burdened with a cancer incidence more than double the national average, is alarming. "The incidence of cancer in Kerala is above the national average for both men and women, highlighting the urgent need for stronger preventive measures," he said. On a positive note, Dr. Mathur acknowledged that Kerala's cancer survival rates are comparatively favorable. Dr. Suresh H. Advani, considered the father of cancer treatment in India, noted a concerning increase in breast and thyroid cancer among women in Kerala in recent years. "Thyroid cancer is so prevalent that even in smaller cities, there are 3-4 surgeries every week," he remarked. Dr. Narayanankutty Warrier, Medical Director of the MVR Cancer Centre and Research Institute, pointed to a 300% increase in breast cancer cases over the last 25 years. He noted that the high prevalence of diabetes in the population is a major driver of lifestyle-related diseases.
Time of India
28-06-2025
- Health
- Time of India
New study warns of rising cancer burden in Kerala
T'puram: A recent study presented at the Kerala Cancer Conclave 2025 reveals alarming cancer trends in the state, with Kerala reporting an average 88,460 cases annually—43,110 among males and 45,350 among females. The national average stands at 1.56 million cases, making Kerala's contribution significant at nearly 5.7% of India's total cancer burden. By 2030, projections indicate a further rise to 43,930 cases in men and 45,813 in women. The report presented by Prof Prashant Mathur, Director, ICMR-National Center for Disease Informatics and Research, Bengaluru, points to stark gender-based disparities in cancer prevalence. Among men, lung cancer leads at 14%, followed by oral cavity (10%), colorectal (10%), prostate (9%), and liver cancers (8%). For women, breast cancer dominates at 34%, with thyroid (11%), colorectal (9%), uterine (6%), and ovarian cancers (4%) following. Among males, the most common cancers were lung (14%), oral cavity (10%), colorectum (10%), prostate (9%), and Jliver (8%). In females, breast cancer accounted for a striking 34%, followed by thyroid (11%), colorectum (9%), corpus uteri (6%), and ovary (4%). Dr Mathur highlighted the rising prevalence of lung, prostate, and liver cancers in men, and breast and thyroid cancers in women. Liver cancer, in particular, continues to show a rapid increase across both genders over the past two decades. In terms of crude mortality rates in Kerala in 2024, lung cancer led among men at 28.9%, followed by liver (18.9%), prostate (11.2%), stomach (8.3%), and mouth (8.3%). For women, breast cancer had the highest crude mortality rate at 37.5%, followed by lung (8.3%), ovary (6.6%), thyroid (6.1%), and cervix uteri (5.2%). Lung cancer mortality among men in the state is 28.9%, while the national average is only 7.8%. For breast cancer in women, Kerala's mortality rate is 37.5%, far above the national average of 14.9%.
